artenimol has been researched along with gemcitabine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, XW; Chen, H; Gao, Y; Jiang, HC; Kong, R; Pan, SH; Sun, B; Wang, SJ; Xue, DB | 1 |
| Bai, XW; Chen, H; Jiang, HC; Kong, R; Li, J; Pan, SH; Sun, B; Wang, SJ; Xue, DB | 1 |
| Chen, T; Gao, W; Zhao, C | 1 |
| Chen, J; Chen, T; Gao, W; Li, T; Liu, H; Qin, G; Wu, S; Xi, G; Zhao, C | 1 |
| Chen, X; Shen, N; Tang, Z; Wang, G; Yang, S; Zhang, D | 1 |
5 other study(ies) available for artenimol and gemcitabine
| Article | Year |
|---|---|
Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Cell Growth Processes; Cell Survival; Deoxycytidine; DNA, Neoplasm; Down-Regulation; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2010 |
[Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Synergistic induction of apoptosis in A549 cells by dihydroartemisinin and gemcitabine.
Topics: Antineoplastic Agents; Apoptosis; Artemisinins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Cell Line, Tumor; Deoxycytidine; Drug Synergism; fas Receptor; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Reactive Oxygen Species; Signal Transduction | 2014 |
Potent proapoptotic actions of dihydroartemisinin in gemcitabine-resistant A549 cells.
Topics: Antineoplastic Agents; Apoptosis; Artemisinins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Membrane Potential, Mitochondrial; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering | 2014 |
Dihydroartemisinin increases gemcitabine therapeutic efficacy in ovarian cancer by inducing reactive oxygen species.
Topics: Animals; Antimetabolites, Antineoplastic; Artemisinins; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Female; Gemcitabine; Heme Oxygenase-1; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Reactive Oxygen Species; Signal Transduction; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |